Thomas Jefferson University

Daniel Sahm

TitleVolunteer Faculty
InstitutionThomas Jefferson University
DepartmentFaculty Records
Address1025 Walnut St.
Philadelphia PA 19107
Phone302-298-7969
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Deryke CA, Wise MG, Bauer KA, Siddiqui F, Young K, Motyl MR, Sahm DF. Antimicrobial activity of imipenem/relebactam and comparator agents against Gram-negative isolates collected from pediatric patients: SMART 2018-2022 Global Surveillance. J Pediatric Infect Dis Soc. 2025 Jan 10. PMID: 39789315.
      Citations:    
    2. Hameed P S, Kotakonda H, Sharma S, Nandishaiah R, Katagihallimath N, Rao R, Sadler C, Slater I, Morton M, Chandrasekaran A, Griffen E, Pillai D, Reddy S, Bharatham N, Venkatesan S, Jonnalagadda V, Jayaraman R, Nanjundappa M, Sharma M, Raveendran S, Rajagopal S, Tumma H, Watters A, Becker H, Lindley J, Flamm R, Huband M, Sahm D, Hackel M, Mathur T, Kolamunnage-Dona R, Unsworth J, Mcentee L, Farrington N, Manickam D, Chandrashekara N, Jayachandiran S, Reddy H, Shanker S, Richard V, Thomas T, Nagaraj S, Datta S, Sambandamurthy V, Ramachandran V, Clay R, Tomayko J, Das S, V B. BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections. Nat Commun. 2024 Sep 18; 15(1):8202. PMID: 39294149.
      Citations:    
    3. Wise MG, DeRyke CA, Alekseeva I, Siddiqui F, Young K, Motyl MR, Sahm DF. Susceptibility of Gram-negative pathogens collected in Israel to ceftolozane/tazobactam, imipenem/relebactam and comparators: SMART 2018-22. JAC Antimicrob Resist. 2024 Oct; 6(5):dlae150. PMID: 39291180.
      Citations:    
    4. Karlowsky JA, Wise MG, Hackel MA, Six DA, Uehara T, Daigle DM, Pevear DC, Moeck G, Sahm DF. Cefepime-taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018-22. J Antimicrob Chemother. 2024 Sep 17. PMID: 39287999.
      Citations:    
    5. Karlowsky JA, Lob SH, Siddiqui F, Polis T, Vallejo JL, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam and imipenem/relebactam against Gram-negative clinical isolates collected in Mexico-SMART 2017-2021. JAC Antimicrob Resist. 2024 Jun; 6(3):dlae077. PMID: 38799180.
      Citations:    
    6. Karlowsky JA, Lob SH, Hawser SP, Kothari N, Siddiqui F, Alekseeva I, DeRyke CA, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy-SMART 2017-2021. Eur J Clin Microbiol Infect Dis. 2024 May 22. PMID: 38775873.
      Citations:    
    7. Wise MG, Karlowsky JA, Mohamed N, Hermsen ED, Kamat S, Townsend A, Brink A, Soriano A, Paterson DL, Moore LSP, Sahm DF. Global Trends in Carbapenem- and Difficult-to-Treat-Resistance Among World Health Organization Priority Bacterial Pathogens: ATLAS Surveillance Program 2018-2022. J Glob Antimicrob Resist. 2024 Apr 10. PMID: 38608936.
      Citations:    
    8. Estabrook M, Muyldermans A, Sahm D, Pierard D, Stone G, Utt E. Erratum for Estabrook et al., "Epidemiology of Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Study, 2018 to 2019". Antimicrob Agents Chemother. 2024 Feb 13; e0164023. PMID: 38349140.
      Citations:    
    9. Karlowsky JA, Lob SH, Bauer KA, Esterly J, Siddiqui F, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam, imipenem/relebactam and ceftazidime/avibactam against clinical Gram-negative isolates-SMART United States 2019-21. JAC Antimicrob Resist. 2024 Feb; 6(1):dlad152. PMID: 38222461.
      Citations:    
    10. Karlowsky JA, Wise MG, Chen WT, Siddiqui F, Young K, Motyl MR, Sahm DF. Susceptibility of Gram-negative isolates collected in South Korea to imipenem/relebactam and comparator agents-SMART 2018-21. JAC Antimicrob Resist. 2024 Feb; 6(1):dlad149. PMID: 38161963.
      Citations:    
    11. Takemura M, Nakamura R, Ota M, Nakai R, Sahm DF, Hackel MA, Yamano Y. In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia complex, including carbapenem-non-susceptible isolates. Antimicrob Agents Chemother. 2023 Nov 16; e0034623. PMID: 37971240.
      Citations:    
    12. Wise MG, Karlowsky JA, Chen WT, Siddiqui F, Young K, Motyl MR, Sahm DF. Susceptibility of gram-negative isolates collected in Taiwan to imipenem/relebactam and comparator agents - SMART 2018-2021. J Formos Med Assoc. 2023 Sep 20. PMID: 37735013.
      Citations:    
    13. Wise MG, Karlowsky JA, Hackel MA, Harti MA, Ntshole BME, Njagua EN, Oladele R, Samuel C, Khan S, Wadula J, Lowman W, Lembede BW, Sahm DF. In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa from Sub-Saharan Africa: ATLAS Global Surveillance Program 2017-2021. J Glob Antimicrob Resist. 2023 Sep 12. PMID: 37709139.
      Citations:    
    14. Karlowsky JA, Lob SH, Hawser SP, Kothari N, Siddiqui F, Alekseeva I, DeRyke CA, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in central and northern Europe (Belgium, Norway, Sweden, Switzerland)-SMART 2017-21. JAC Antimicrob Resist. 2023 Aug; 5(4):dlad098. PMID: 37577157.
      Citations:    
    15. Wise MG, Karlowsky JA, Mohamed N, Kamat S, Sahm DF. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021. Eur J Clin Microbiol Infect Dis. 2023 Sep; 42(9):1135-1143. PMID: 37526796.
      Citations:    
    16. Karlowsky JA, Wise MG, Hsieh TC, Lu HC, Chen WT, Cheng MH, Siddiqui F, Young K, Motyl MR, Sahm DF. Temporal and Geographical Prevalence of Carbapenem-Resistant Pseudomonas aeruginosa and the In Vitro Activity of Ceftolozane/Tazobactam and Comparators in Taiwan - SMART 2012-2021. J Glob Antimicrob Resist. 2023 Jul 05. PMID: 37419182.
      Citations:    
    17. Takemura M, Wise MG, Hackel MA, Sahm DF, Yamano Y. In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019). J Antimicrob Chemother. 2023 Jun 30. PMID: 37390312.
      Citations:    
    18. Karlowsky JA, Lob SH, Estabrook MA, Siddiqui F, DeRyke CA, Young K, Motyl MR, Sahm DF. Susceptibility profile and ?-lactamase content of global Pseudomonas aeruginosa isolates resistant to ceftolozane/tazobactam and/or imipenem/relebactam-SMART 2016-21. JAC Antimicrob Resist. 2023 Jun; 5(3):dlad080. PMID: 37388237.
      Citations:    
    19. Karlowsky JA, Lob SH, Chen WT, DeRyke CA, Siddiqui F, Young K, Motyl MR, Sahm DF. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020. Int J Antimicrob Agents. 2023 Jun 22; 106900. PMID: 37354921.
      Citations:    
    20. Wise MG, Karlowsky JA, Hackel MA, Takemura M, Yamano Y, Echols R, Sahm DF. In Vitro Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined ?-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014-2019. Microb Drug Resist. 2023 May 30. PMID: 37253158.
      Citations:    
    21. Gales AC, Stone G, Sahm DF, Wise MG, Utt E. Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017-2019. J Antimicrob Chemother. 2023 May 10. PMID: 37161662.
      Citations:    
    22. Karlowsky JA, Hackel MA, Takemura M, Yamano Y, Echols R, Sahm DF. Erratum for Karlowsky et al., "In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019". Antimicrob Agents Chemother. 2023 May 08; e0042723. PMID: 37154749.
      Citations:    
    23. Karlowsky JA, Lob SH, Siddiqui F, Pavia J, DeRyke CA, Young K, Motyl MR, Sahm DF. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018?2020. Braz J Infect Dis. 2023 May 08; 27(3):102775. PMID: 37169345.
      Citations:    
    24. Karlowsky JA, Lob SH, Khan TK, Chen WT, Woo PCY, Seto WH, Ip M, Leung SWM, Wong QW, Chau RWY, DeRyke CA, Young K, Motyl MR, Sahm DF. Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017-2020. J Glob Antimicrob Resist. 2023 Apr 20. PMID: 37086892.
      Citations:    
    25. Estabrook M, Muyldermans A, Sahm D, Pierard D, Stone G, Utt E. Epidemiology of Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Study, 2018 to 2019. Antimicrob Agents Chemother. 2023 Apr 19; e0140622. PMID: 37074173.
      Citations:    
    26. Wise MG, Karlowsky JA, Luengas EL, Valdez RR, Sahm DF. Epidemiology and in vitro activity of ceftazidime-avibactam and comparator agents against multidrug-resistant isolates of Enterobacterales and Pseudomonas aeruginosa collected in Latin America as part of the ATLAS surveillance program in 2015?2020. Braz J Infect Dis. 2023 Mar 25; 102759. PMID: 36977498.
      Citations:    
    27. Karlowsky JA, Lob SH, Siddiqui F, Akrich B, DeRyke CA, Young K, Motyl MR, Hawser SP, Sahm DF. In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020. Int J Antimicrob Agents. 2023 Mar 04; 106772. PMID: 36878411.
      Citations:    
    28. Karlowsky JA, Lob SH, Siddiqui F, Akrich B, DeRyke CA, Young K, Motyl MR, Hawser SP, Sahm DF. In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018-2020. J Med Microbiol. 2023 Feb; 72(2). PMID: 36763081.
      Citations:    
    29. Lob SH, Hawser SP, Siddiqui F, Alekseeva I, DeRyke CA, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland-SMART 2017-2020. Eur J Clin Microbiol Infect Dis. 2023 Mar; 42(3):365-370. PMID: 36670243.
      Citations:    
    30. Karlowsky JA, Lob SH, Akrich B, DeRyke CA, Siddiqui F, Young K, Motyl MR, Hawser SP, Sahm DF. In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with lower respiratory tract infections in Western Europe: SMART 2018-20. JAC Antimicrob Resist. 2023 Feb; 5(1):dlad003. PMID: 36694850.
      Citations:    
    31. Humphries RM, Janssen H, Hey-Hadavi JH, Hackel M, Sahm D. Multidrug-resistant Gram-negative bacilli recovered from respiratory and blood specimens from adults: the ATLAS surveillance program in European hospitals, 2018-2020. Int J Antimicrob Agents. 2023 Feb; 61(2):106724. PMID: 36642231.
      Citations:    
    32. Karlowsky JA, Hackel MA, Stone GG, Sahm DF. In Vitro Activity of Ceftibuten-Avibactam against ?-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program. Antimicrob Agents Chemother. 2023 01 24; 67(1):e0134622. PMID: 36602322.
      Citations:    
    33. Karlowsky JA, Hackel MA, Wise MG, Six DA, Uehara T, Daigle DM, Cusick SM, Pevear DC, Moeck G, Sahm DF. In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program. Antimicrob Agents Chemother. 2023 01 24; 67(1):e0128122. PMID: 36541767.
      Citations:    
    34. Kohira N, Hackel MA, Oota M, Takemura M, Hu F, Mizuno H, Sahm DF, Yamano Y. In Vitro Antibacterial Activities of Cefiderocol Against Gram-Negative Clinical Strains Isolated From China in 2020. J Glob Antimicrob Resist. 2022 Dec 10. PMID: 36513320.
      Citations:    
    35. Karlowsky JA, Wise MG, Hackel MA, Pevear DC, Moeck G, Sahm DF. Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-?-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018-2020 Global Surveillance Collection. Antimicrob Agents Chemother. 2022 11 15; 66(11):e0093422. PMID: 36286518.
      Citations:    
    36. Lob SH, Estabrook MA, DeRyke CA, Alekseeva I, Siddiqui F, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa - Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020. Int J Infect Dis. 2022 Dec; 125:250-257. PMID: 36244599.
      Citations:    
    37. Karlowsky JA, Bouchillon SK, El Mahdy Kotb R, Mohamed N, Stone GG, Sahm DF. Carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa causing infection in Africa and the Middle East: a surveillance study from the ATLAS programme (2018-20). JAC Antimicrob Resist. 2022 Jun; 4(3):dlac060. PMID: 35733913.
      Citations:    
    38. Karlowsky JA, Lob SH, DeRyke CA, Hilbert DW, Wong MT, Young K, Siddiqui F, Motyl MR, Sahm DF. In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020. Antimicrob Agents Chemother. 2022 05 17; 66(5):e0018922. PMID: 35491836.
      Citations:    
    39. Karlowsky JA, Bouchillon SK, Benaouda A, Soraa N, Zerouali K, Mohamed N, Alami T, Sahm DF. Antimicrobial susceptibility testing of clinical isolates of Gram-negative bacilli collected in Morocco by the ATLAS Global Surveillance Program from 2018 to 2020. J Glob Antimicrob Resist. 2022 09; 30:23-30. PMID: 35447385.
      Citations:    
    40. Karlowsky JA, Lob SH, Khan A, Chen WT, Woo PCY, Seto WH, Ip M, Leung S, Wong QW, Chau RWY, DeRyke CA, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019. J Med Microbiol. 2022 Apr; 71(4). PMID: 35451945.
      Citations:    
    41. Simner PJ, Musser KA, Mitchell K, Wise MG, Lewis S, Yee R, Bergman Y, Good CE, Abdelhamed AM, Li H, Laseman EM, Sahm D, Pitzer K, Quan J, Walker GT, Jacobs MR, Rhoads DD. Multicenter Evaluation of the Acuitas AMR Gene Panel for Detection of an Extended Panel of Antimicrobial Resistance Genes among Bacterial Isolates. J Clin Microbiol. 2022 03 16; 60(3):e0209821. PMID: 35138924.
      Citations:    
    42. Bispo PJM, Sahm DF, Asbell PA. A Systematic Review of Multi-decade Antibiotic Resistance Data for Ocular Bacterial Pathogens in the United States. Ophthalmol Ther. 2022 Apr; 11(2):503-520. PMID: 35113406.
      Citations:    
    43. Karlowsky JA, Lob SH, DeRyke CA, Siddiqui F, Young K, Motyl MR, Sahm DF. Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019. Int J Antimicrob Agents. 2022 Mar; 59(3):106535. PMID: 35091052.
      Citations:    
    44. Hackel MA, Karlowsky JA, Canino MA, Sahm DF, Scangarella-Oman NE. In Vitro Activity of Gepotidacin against Gram-Negative and Gram-Positive Anaerobes. Antimicrob Agents Chemother. 2022 02 15; 66(2):e0216521. PMID: 34930028.
      Citations:    
    45. Lob SH, Kazmierczak KM, Chen WT, Siddiqui F, DeRyke CA, Young K, Motyl MR, Sahm DF. In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019. J Glob Antimicrob Resist. 2022 06; 29:527-533. PMID: 34896336.
      Citations:    
    46. Karlowsky JA, Hackel MA, Takemura M, Yamano Y, Echols R, Sahm DF. In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019. Antimicrob Agents Chemother. 2022 02 15; 66(2):e0199021. PMID: 34807757.
      Citations:    
    47. Karlowsky JA, Kazmierczak KM, Valente MLNF, Luengas EL, Baudrit M, Quintana A, Irani P, Stone GG, Sahm DF. In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017-2019. Braz J Infect Dis. 2021 Nov-Dec; 25(6):101647. PMID: 34774471.
      Citations:    
    48. Karlowsky JA, Hackel MA, Sahm DF. In Vitro Activity of Ceftibuten/VNRX-5236 against Urinary Tract Infection Isolates of Antimicrobial-Resistant Enterobacterales. Antimicrob Agents Chemother. 2022 01 18; 66(1):e0130421. PMID: 34662183.
      Citations:    
    49. Kazmierczak KM, Karlowsky JA, de Jonge BLM, Stone GG, Sahm DF. Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Program, 2012 to 2017. Antimicrob Agents Chemother. 2021 06 17; 65(7):e0200020. PMID: 33972241.
      Citations:    
    50. Lob SH, DePestel DD, DeRyke CA, Kazmierczak KM, Young K, Motyl MR, Sahm DF. Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards-SMART United States 2017-2019. Open Forum Infect Dis. 2021 Jul; 8(7):ofab320. PMID: 34307727.
      Citations:    
    51. Karlowsky JA, Lob SH, Raddatz J, DePestel DD, Young K, Motyl MR, Sahm DF. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017. Clin Infect Dis. 2021 06 15; 72(12):2112-2120. PMID: 32246147.
      Citations:    
    52. Karlowsky JA, Bouchillon SK, El Mahdy Kotb R, Mohamed N, Stone GG, Sahm DF. In vitro activity of ceftazidime/avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from Middle Eastern and African countries: ATLAS global surveillance programme 2015-18. JAC Antimicrob Resist. 2021 Jun; 3(2):dlab067. PMID: 34223129.
      Citations:    
    53. Lob SH, Hackel MA, Young K, Motyl MR, Sahm DF. Activity of imipenem/relebactam and comparators against gram-negative pathogens from patients with bloodstream infections in the United States and Canada - SMART 2018-2019. Diagn Microbiol Infect Dis. 2021 Aug; 100(4):115421. PMID: 34082265.
      Citations:    
    54. Karlowsky JA, Lob SH, Young K, Motyl MR, Sahm DF. In Vitro Activity of Imipenem/Relebactam Against Gram-Negative Bacilli from Pediatric Patients-Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance program 2015-2017. J Pediatric Infect Dis Soc. 2021 Apr 03; 10(3):274-281. PMID: 32535630.
      Citations:    
    55. Karlowsky JA, Lob SH, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections - SMART United States 2018-2019. BMC Microbiol. 2021 03 06; 21(1):74. PMID: 33676406.
      Citations:    
    56. Estabrook M, Kazmierczak KM, Wise M, Arhin FF, Stone GG, Sahm DF. Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012-2017. J Glob Antimicrob Resist. 2021 03; 24:316-320. PMID: 33524556.
      Citations:    
    57. Karlowsky JA, Hackel MA, Bouchillon SLK, Lowman W, Kotb REM, Mohamed N, Stone GG, Sahm DF. In vitro activity of ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in the Middle East and Africa: AWARE global surveillance programme 2015-2018. J Glob Antimicrob Resist. 2021 03; 24:249-256. PMID: 33373731.
      Citations:    
    58. Karlowsky JA, Hackel MA, Bouchillon SK, Sahm DF. In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems. Antimicrob Agents Chemother. 2020 11 17; 64(12). PMID: 32928739.
      Citations:    
    59. Sato T, Ito A, Ishioka Y, Matsumoto S, Rokushima M, Kazmierczak KM, Hackel M, Sahm DF, Yamano Y. Escherichia coli strains possessing a four amino acid YRIN insertion in PBP3 identified as part of the SIDERO-WT-2014 surveillance study. JAC Antimicrob Resist. 2020 Sep; 2(3):dlaa081. PMID: 34223033.
      Citations:    
    60. Kohira N, Hackel MA, Ishioka Y, Kuroiwa M, Sahm DF, Sato T, Maki H, Yamano Y. Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014). J Glob Antimicrob Resist. 2020 09; 22:738-741. PMID: 32702396.
      Citations:    
    61. Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF. Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013-17. J Antimicrob Chemother. 2020 05 01; 75(5):1165-1173. PMID: 32040168.
      Citations:    
    62. Asbell PA, Sanfilippo CM, Sahm DF, DeCory HH. Trends in Antibiotic Resistance Among Ocular Microorganisms in the United States From 2009 to 2018. JAMA Ophthalmol. 2020 05 01; 138(5):439-450. PMID: 32271355.
      Citations:    
    63. Lob SH, Karlowsky JA, Young K, Motyl MR, Hawser S, Kothari ND, Sahm DF. In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015-2017. J Med Microbiol. 2020 Feb; 69(2):207-217. PMID: 31976856.
      Citations:    
    64. Karlowsky JA, Kazmierczak KM, Young K, Motyl MR, Sahm DF. In vitro activity of ceftolozane/tazobactam against phenotypically defined extended-spectrum ?-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016). Diagn Microbiol Infect Dis. 2020 Apr; 96(4):114925. PMID: 31954597.
      Citations:    
    65. Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF. In-vitro activity of imipenem/relebactam and key ?-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017. Int J Antimicrob Agents. 2020 Jan; 55(1):105841. PMID: 31704217.
      Citations:    
    66. Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF. In vitro activity of imipenem/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015-2017. J Glob Antimicrob Resist. 2020 06; 21:223-228. PMID: 31698105.
      Citations:    
    67. Lob SH, Karlowsky JA, Young K, Motyl MR, Hawser S, Kothari ND, Gueny ME, Sahm DF. Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17. J Antimicrob Chemother. 2019 08 01; 74(8):2284-2288. PMID: 31086960.
      Citations:    
    68. Lob SH, Hoban DJ, Young K, Motyl MR, Sahm DF. Activity of ceftolozane-tazobactam and comparators against Pseudomonas aeruginosa from patients in different risk strata - SMART United States 2016-2017. J Glob Antimicrob Resist. 2020 03; 20:209-213. PMID: 31351246.
      Citations:    
    69. Young K, Painter RE, Raghoobar SL, Hairston NN, Racine F, Wisniewski D, Balibar CJ, Villafania A, Zhang R, Sahm DF, Blizzard T, Murgolo N, Hammond ML, Motyl MR. In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa. BMC Microbiol. 2019 07 04; 19(1):150. PMID: 31272373.
      Citations:    
    70. Karlowsky JA, Lob SH, Young K, Motyl MR, Sahm DF. Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017. Diagn Microbiol Infect Dis. 2019 Oct; 95(2):212-215. PMID: 31174995.
      Citations:    
    71. Walker GT, Quan J, Higgins SG, Toraskar N, Chang W, Saeed A, Sapiro V, Pitzer K, Whitfield N, Lopansri BK, Motyl M, Sahm D. Predicting Antibiotic Resistance in Gram-Negative Bacilli from Resistance Genes. Antimicrob Agents Chemother. 2019 04; 63(4). PMID: 30917985.
      Citations:    
    72. Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF. In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015. Antimicrob Agents Chemother. 2019 04; 63(4). PMID: 30670424.
      Citations:    
    73. Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth. Diagn Microbiol Infect Dis. 2019 Aug; 94(4):321-325. PMID: 31029489.
      Citations:    
    74. Kazmierczak KM, Bradford PA, Stone GG, de Jonge BLM, Sahm DF. In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015. Antimicrob Agents Chemother. 2018 12; 62(12). PMID: 30249690.
      Citations:    
    75. Karlowsky JA, Hackel MA, Tsuji M, Yamano Y, Echols R, Sahm DF. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015. Int J Antimicrob Agents. 2019 Apr; 53(4):456-466. PMID: 30471402.
      Citations:    
    76. Kazmierczak KM, Tsuji M, Wise MG, Hackel M, Yamano Y, Echols R, Sahm DF. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-?-lactamase-producing isolates (SIDERO-WT-2014 Study). Int J Antimicrob Agents. 2019 Feb; 53(2):177-184. PMID: 30395986.
      Citations:    
    77. Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF. In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012-15. J Antimicrob Chemother. 2018 10 01; 73(10):2782-2788. PMID: 30010894.
      Citations:    
    78. Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15. J Antimicrob Chemother. 2018 10 01; 73(10):2777-2781. PMID: 30010951.
      Citations:    
    79. Karlowsky JA, Lob SH, Young K, Motyl MR, Sahm DF. Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015-2016. J Glob Antimicrob Resist. 2018 12; 15:140-147. PMID: 30071354.
      Citations:    
    80. Karlowsky JA, Lob SH, Kazmierczak KM, Hawser SP, Magnet S, Young K, Motyl MR, Sahm DF. In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme. J Antimicrob Chemother. 2018 07 01; 73(7):1872-1879. PMID: 29659861.
      Citations:    
    81. Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF. In Vitro Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program. Antimicrob Agents Chemother. 2018 07; 62(7). PMID: 29760135.
      Citations:    
    82. Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF. In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015. Antimicrob Agents Chemother. 2018 07; 62(7). PMID: 29760124.
      Citations:    
    83. Lob SH, Hoban DJ, Young K, Motyl MR, Sahm DF. Activity of imipenem/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015-2016. J Glob Antimicrob Resist. 2018 12; 15:12-19. PMID: 29857057.
      Citations:    
    84. Lob SH, Hackel MA, Hoban DJ, Young K, Motyl MR, Sahm DF. Activity of Ertapenem against Enterobacteriaceae in seven global regions-SMART 2012-2016. Eur J Clin Microbiol Infect Dis. 2018 Aug; 37(8):1481-1489. PMID: 29754209.
      Citations:    
    85. Wise MG, Estabrook MA, Sahm DF, Stone GG, Kazmierczak KM. Prevalence of mcr-type genes among colistin-resistant Enterobacteriaceae collected in 2014-2016 as part of the INFORM global surveillance program. PLoS One. 2018; 13(4):e0195281. PMID: 29608599.
      Citations:    
    86. Hackel MA, Iaconis JP, Karlowsky JA, Sahm DF. Analysis of Potential ?-Lactam Surrogates To Predict In Vitro Susceptibility and Resistance to Ceftaroline for Clinical Isolates of Enterobacteriaceae. J Clin Microbiol. 2018 04; 56(4). PMID: 29436424.
      Citations:    
    87. Wise MG, Horvath E, Young K, Sahm DF, Kazmierczak KM. Global survey of Klebsiella pneumoniae major porins from ertapenem non-susceptible isolates lacking carbapenemases. J Med Microbiol. 2018 Mar; 67(3):289-295. PMID: 29458684.
      Citations:    
    88. Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016. Antimicrob Agents Chemother. 2018 02; 62(2). PMID: 29158270.
      Citations:    
    89. Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF. In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae. Antimicrob Agents Chemother. 2018 01; 62(1). PMID: 29084745.
      Citations:    
    90. Huang DB, Hawser S, Gemmell CG, Sahm DF. In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study. Can J Infect Dis Med Microbiol. 2017; 2017:3948626. PMID: 29527229.
      Citations:    
    91. Karlowsky JA, Kazmierczak KM, de Jonge BLM, Hackel MA, Sahm DF, Bradford PA. In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015. Antimicrob Agents Chemother. 2017 09; 61(9). PMID: 28630192.
      Citations:    
    92. Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study). Antimicrob Agents Chemother. 2017 09; 61(9). PMID: 28630181.
      Citations:    
    93. Hackel MA, Karlowsky JA, Dressel D, Sahm DF. Determination of Disk Diffusion and MIC Quality Control Ranges for Nafithromycin (WCK 4873), a New Lactone-Ketolide. J Clin Microbiol. 2017 10; 55(10):3021-3027. PMID: 28747372.
      Citations:    
    94. Karlowsky JA, Hackel MA, Bouchillon SK, Alder J, Sahm DF. In Vitro activities of Tedizolid and comparator antimicrobial agents against clinical isolates of Staphylococcus aureus collected in 12 countries from 2014 to 2016. Diagn Microbiol Infect Dis. 2017 Oct; 89(2):151-157. PMID: 28793964.
      Citations:    
    95. Lob SH, Hackel MA, Kazmierczak KM, Young K, Motyl MR, Karlowsky JA, Sahm DF. In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program). Antimicrob Agents Chemother. 2017 06; 61(6). PMID: 28320716.
      Citations:    
    96. Cunningham SA, Limbago B, Traczewski M, Anderson K, Hackel M, Hindler J, Sahm D, Alyanak E, Lawsin A, Gulvik CA, de Man TJB, Mandrekar JN, Schuetz AN, Jenkins S, Humphries R, Palavecino E, Vasoo S, Patel R. Multicenter Performance Assessment of Carba NP Test. J Clin Microbiol. 2017 06; 55(6):1954-1960. PMID: 28404676.
      Citations:    
    97. Karlowsky JA, Hoban DJ, Hackel MA, Lob SH, Sahm DF. Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013-2015. Braz J Infect Dis. 2017 May - Jun; 21(3):343-348. PMID: 28399424.
      Citations:    
    98. Karlowsky JA, Lob SH, Kazmierczak KM, Badal RE, Young K, Motyl MR, Sahm DF. In Vitro Activity of Imipenem against Carbapenemase-Positive Enterobacteriaceae Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014. J Clin Microbiol. 2017 06; 55(6):1638-1649. PMID: 28298454.
      Citations:    
    99. Lob SH, Hackel MA, Kazmierczak KM, Hoban DJ, Young K, Motyl MR, Karlowsky JA, Sahm DF. Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program. Diagn Microbiol Infect Dis. 2017 Jun; 88(2):171-176. PMID: 28291628.
      Citations:    
    100. Lob SH, Badal RE, Hackel MA, Sahm DF. Epidemiology and Antimicrobial Susceptibility of Gram-Negative Pathogens Causing Intra-abdominal Infections in Pediatric Patients in Europe-SMART 2011-2014. J Pediatric Infect Dis Soc. 2017 Mar 01; 6(1):72-79. PMID: 26883618.
      Citations:    
    101. Karlowsky JA, Hoban DJ, Hackel MA, Lob SH, Sahm DF. Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015. J Med Microbiol. 2017 Jan; 66(1):61-69. PMID: 28051952.
      Citations:    
    102. Bensaci M, Sahm D. Surveillance of tedizolid activity and resistance: In vitro susceptibility of Gram-positive pathogens collected over 5 years from the United States and Europe. Diagn Microbiol Infect Dis. 2017 Feb; 87(2):133-138. PMID: 27866673.
      Citations:    
    103. Corey GR, Arhin FF, Wikler MA, Sahm DF, Kreiswirth BN, Mediavilla JR, Good S, Fiset C, Jiang H, Moeck G, Kabler H, Green S, O'Riordan W. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 2016 Nov; 48(5):528-534. PMID: 27665522.
      Citations:    
    104. Bartsch SM, Huang SS, Wong KF, Slayton RB, McKinnell JA, Sahm DF, Kazmierczak K, Mueller LE, Jernigan JA, Lee BY. Impact of Delays between Clinical and Laboratory Standards Institute and Food and Drug Administration Revisions of Interpretive Criteria for Carbapenem-Resistant Enterobacteriaceae. J Clin Microbiol. 2016 11; 54(11):2757-2762. PMID: 27582516.
      Citations:    
    105. Nichols WW, de Jonge BL, Kazmierczak KM, Karlowsky JA, Sahm DF. In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother. 2016 08; 60(8):4743-9. PMID: 27216074.
      Citations:    
    106. Kazmierczak KM, Biedenbach DJ, Hackel M, Rabine S, de Jonge BL, Bouchillon SK, Sahm DF, Bradford PA. Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam. Antimicrob Agents Chemother. 2016 08; 60(8):4490-500. PMID: 27161636.
      Citations:    
    107. Karlowsky JA, Biedenbach DJ, Bouchillon SK, Hackel M, Iaconis JP, Sahm DF. In vitro activity of Ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012-2014. Diagn Microbiol Infect Dis. 2016 Oct; 86(2):194-9. PMID: 27461798.
      Citations:    
    108. Lob SH, Biedenbach DJ, Badal RE, Kazmierczak KM, Sahm DF. Discrepancy between genotypic and phenotypic extended-spectrum ?-lactamase rates in Escherichia coli from intra-abdominal infections in the USA. J Med Microbiol. 2016 Sep; 65(9):905-909. PMID: 27392786.
      Citations:    
    109. Zalacain M, Biedenbach DJ, Badal RE, Young K, Motyl M, Sahm DF. Pathogen Prevalence and Antimicrobial Susceptibility Among Enterobacteriaceae Causing Hospital-associated Intra-abdominal Infections in Adults in the United States (2012-2013). Clin Ther. 2016 Jun; 38(6):1510-1521. PMID: 27234360.
      Citations:    
    110. Lob SH, Nicolle LE, Hoban DJ, Kazmierczak KM, Badal RE, Sahm DF. Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010-2014. Diagn Microbiol Infect Dis. 2016 Aug; 85(4):459-65. PMID: 27306116.
      Citations:    
    111. Karlowsky JA, Biedenbach DJ, Kazmierczak KM, Stone GG, Sahm DF. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC ?-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014. Antimicrob Agents Chemother. 2016 05; 60(5):2849-57. PMID: 26926635.
      Citations:    
    112. de Jonge BL, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW. In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014). Antimicrob Agents Chemother. 2016 05; 60(5):3163-9. PMID: 26926648.
      Citations:    
    113. Lob SH, Hoban DJ, Sahm DF, Badal RE. Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. Int J Antimicrob Agents. 2016 Apr; 47(4):317-23. PMID: 27020541.
      Citations:    
    114. Traczewski MM, Deane J, Sahm D, Brown SD, Chesnel L. Impact of Variations in Test Method Parameters on In Vitro Activity of Surotomycin against Clostridium difficile and Surotomycin Quality Control Limits for Broth Microdilution and Agar Dilution Susceptibility Testing. J Clin Microbiol. 2016 Mar; 54(3):749-53. PMID: 26677246.
      Citations:    
    115. Bradford PA, Kazmierczak KM, Biedenbach DJ, Wise MG, Hackel M, Sahm DF. Correlation of ?-Lactamase Production and Colistin Resistance among Enterobacteriaceae Isolates from a Global Surveillance Program. Antimicrob Agents Chemother. 2015 Dec 14; 60(3):1385-92. PMID: 26666920.
      Citations:    
    116. Kazmierczak KM, Rabine S, Hackel M, McLaughlin RE, Biedenbach DJ, Bouchillon SK, Sahm DF, Bradford PA. Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-?-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016 Feb; 60(2):1067-78. PMID: 26643349.
      Citations:    
    117. Asbell PA, Sanfilippo CM, Pillar CM, DeCory HH, Sahm DF, Morris TW. Antibiotic Resistance Among Ocular Pathogens in the United States: Five-Year Results From the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study. JAMA Ophthalmol. 2015 Dec; 133(12):1445-54. PMID: 26502312.
      Citations:    
    118. Karlowsky JA, Biedenbach DJ, Bouchillon SK, Iaconis JP, Reiszner E, Sahm DF. In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme. J Antimicrob Chemother. 2016 Jan; 71(1):162-9. PMID: 26503667.
      Citations:    
    119. Biedenbach DJ, Alm RA, Lahiri SD, Reiszner E, Hoban DJ, Sahm DF, Bouchillon SK, Ambler JE. In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program. Antimicrob Agents Chemother. 2016 01; 60(1):343-7. PMID: 26503659.
      Citations:    
    120. Biedenbach DJ, Arhin FF, Moeck G, Lynch TF, Sahm DF. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014. Int J Antimicrob Agents. 2015 Dec; 46(6):674-81. PMID: 26541881.
      Citations:    
    121. Hoban D, Biedenbach D, Sahm D, Reiszner E, Iaconis J. Activity of ceftaroline and comparators against pathogens isolated from skin and soft tissue infections in Latin America - results of AWARE surveillance 2012. Braz J Infect Dis. 2015 Nov-Dec; 19(6):596-603. PMID: 26481631.
      Citations:    
    122. Biedenbach DJ, Hoban DJ, Reiszner E, Lahiri SD, Alm RA, Sahm DF, Bouchillon SK, Ambler JE. In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program. Antimicrob Agents Chemother. 2015 Dec; 59(12):7873-7. PMID: 26416860.
      Citations:    
    123. Biedenbach DJ, Huband MD, Hackel M, de Jonge BL, Sahm DF, Bradford PA. In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens. Antimicrob Agents Chemother. 2015 Oct; 59(10):6053-63. PMID: 26195518.
      Citations:    
    124. Biedenbach DJ, Kazmierczak K, Bouchillon SK, Sahm DF, Bradford PA. In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013. Antimicrob Agents Chemother. 2015 Jul; 59(7):4239-48. PMID: 25963984.
      Citations:    
    125. Dunne MW, Sahm D, Puttagunta S. Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies. Ann Clin Microbiol Antimicrob. 2015 Apr 02; 14:19. PMID: 25885674.
      Citations:    
    126. Lob SH, Kazmierczak KM, Badal RE, Hackel MA, Bouchillon SK, Biedenbach DJ, Sahm DF. Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013. Antimicrob Agents Chemother. 2015; 59(6):3606-10. PMID: 25801558.
      Citations:    
    127. Grossman TH, Pillar CM, Sahm DF, Sutcliffe JA. In vitro susceptibility testing of eravacycline is unaffected by medium age and nonstandard assay parameters. Antimicrob Agents Chemother. 2015 Apr; 59(4):2426-7. PMID: 25605350.
      Citations:    
    128. Sahm DF, Deane J, Bien PA, Locke JB, Zuill DE, Shaw KJ, Bartizal KF. Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe. Diagn Microbiol Infect Dis. 2015 Feb; 81(2):112-8. PMID: 25488274.
      Citations:    
    129. Locke JB, Zuill DE, Scharn CR, Deane J, Sahm DF, Denys GA, Goering RV, Shaw KJ. Linezolid-resistant Staphylococcus aureus strain 1128105, the first known clinical isolate possessing the cfr multidrug resistance gene. Antimicrob Agents Chemother. 2014 Nov; 58(11):6592-8. PMID: 25155597.
      Citations:    
    130. Locke JB, Zuill DE, Scharn CR, Deane J, Sahm DF, Goering RV, Jenkins SG, Shaw KJ. Identification and characterization of linezolid-resistant cfr-positive Staphylococcus aureus USA300 isolates from a New York City medical center. Antimicrob Agents Chemother. 2014 Nov; 58(11):6949-52. PMID: 25136008.
      Citations:    
    131. Denys GA, Pillar CM, Sahm DF, O'Hanley P, Stephens JT. Five-year longitudinal assessment (2008 to 2012) of E-101 solution activity against clinical target and antimicrobial-resistant pathogens. Antimicrob Agents Chemother. 2014 Aug; 58(8):4911-4. PMID: 24841272.
      Citations:    
    132. Shlaes DM, Sahm D, Opiela C, Spellberg B. The FDA reboot of antibiotic development. Antimicrob Agents Chemother. 2013 Oct; 57(10):4605-7. PMID: 23896479.
      Citations:    
    133. Morrow BJ, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, Peterson J, Davies TA. Activities of carbapenem and comparator agents against contemporary US Pseudomonas aeruginosa isolates from the CAPITAL surveillance program. Diagn Microbiol Infect Dis. 2013 Apr; 75(4):412-6. PMID: 23391609.
      Citations:    
    134. Master RN, Deane J, Opiela C, Sahm DF. Recent trends in resistance to cell envelope-active antibacterial agents among key bacterial pathogens. Ann N Y Acad Sci. 2013 Jan; 1277:1-7. PMID: 23346857.
      Citations:    
    135. Arhin FF, Draghi DC, Pillar CM, Moeck G, Sahm DF. Correlation between oritavancin and vancomycin minimum inhibitory concentrations in staphylococci. Int J Antimicrob Agents. 2012 Dec; 40(6):562-3. PMID: 22871370.
      Citations:    
    136. Queenan AM, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, Peterson J, Davies TA. Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010. Diagn Microbiol Infect Dis. 2012 Jul; 73(3):267-70. PMID: 22579652.
      Citations:    
    137. Keel RA, Kuti JL, Sahm DF, Nicolau DP. Pharmacodynamic evaluation of i.v. antimicrobials against Pseudomonas aeruginosa samples collected from U.S. hospitals. Am J Health Syst Pharm. 2011 Sep 01; 68(17):1619-25. PMID: 21856807.
      Citations:    
    138. Haas W, Pillar CM, Torres M, Morris TW, Sahm DF. Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study. Am J Ophthalmol. 2011 Oct; 152(4):567-574.e3. PMID: 21652021.
      Citations:    
    139. Mera RM, Suaya JA, Amrine-Madsen H, Hogea CS, Miller LA, Lu EP, Sahm DF, O'Hara P, Acosta CJ. Increasing role of Staphylococcus aureus and community-acquired methicillin-resistant Staphylococcus aureus infections in the United States: a 10-year trend of replacement and expansion. Microb Drug Resist. 2011 Jun; 17(2):321-8. PMID: 21417776.
      Citations:    
    140. Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. Impact of new Clinical Laboratory Standards Institute Streptococcus pneumoniae penicillin susceptibility testing breakpoints on reported resistance changes over time. Microb Drug Resist. 2011 Mar; 17(1):47-52. PMID: 21117969.
      Citations:    
    141. Schumacher YO, Sahm D, Baumstark MW, Pottgiesser T. Reticulocytes in athletes: Longitudinal aspects and the influence of long- and short-term exercise. Drug Test Anal. 2010 Oct; 2(10):469-74. PMID: 20886465.
      Citations:    
    142. Arhin FF, Moeck G, Draghi DC, Pillar CM, Sahm DF. Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008. Int J Antimicrob Agents. 2010 Nov; 36(5):474-6. PMID: 20846829.
      Citations:    
    143. Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. Acinetobacter baumannii 2002-2008: increase of carbapenem-associated multiclass resistance in the United States. Microb Drug Resist. 2010 Sep; 16(3):209-15. PMID: 20707714.
      Citations:    
    144. Nadarajah R, Post LR, Liu C, Miller SA, Sahm DF, Brooks GF. Detection of vancomycin-intermediate Staphylococcus aureus with the updated Trek-Sensititre System and the MicroScan System. Comparison with results from the conventional Etest and CLSI standardized MIC methods. Am J Clin Pathol. 2010 Jun; 133(6):844-8. PMID: 20472841.
      Citations:    
    145. Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. The impact of the pneumococcal conjugate vaccine on antimicrobial resistance in the United States since 1996: evidence for a significant rebound by 2007 in many classes of antibiotics. Microb Drug Resist. 2009 Dec; 15(4):261-8. PMID: 19857132.
      Citations:    
    146. Arhin FF, Draghi DC, Pillar CM, Parr TR, Moeck G, Sahm DF. Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates. Antimicrob Agents Chemother. 2009 Nov; 53(11):4762-71. PMID: 19738026.
      Citations:    
    147. Sahm D. In vitro activity of doripenem. Clin Infect Dis. 2009 Aug 15; 49 Suppl 1:S11-6. PMID: 19619017.
      Citations:    
    148. Pillar CM, Torres MK, Brown NP, Shah D, Sahm DF. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother. 2008 Dec; 52(12):4388-99. PMID: 18779357.
      Citations:    
    149. Sahm DF, Brown NP, Draghi DC, Evangelista AT, Yee YC, Thornsberry C. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005. Postgrad Med. 2008 Sep; 120(3 Suppl 1):8-15. PMID: 18931466.
      Citations:    
    150. Davies TA, Yee YC, Amsler K, Goldschmidt R, Sahm DF, Evangelista AT. Sporadic occurrences of fluoroquinolone-resistant Streptococcus pneumoniae in the United States: longitudinal analysis of institutions from the New England and West South Central regions during the TRUST 4-9 (2000-2005) Surveillance Studies. Postgrad Med. 2008 Sep; 120(3 Suppl 1):25-31. PMID: 18931468.
      Citations:    
    151. Davies TA, Yee YC, Bush K, Sahm D, Evangelista A, Goldschmidt R. Effects of the 7-valent pneumococcal conjugate vaccine on U.S. levofloxacin-resistant Streptococcus pneumoniae. Microb Drug Resist. 2008 Sep; 14(3):187-96. PMID: 18707553.
      Citations:    
    152. Thornsberry C, Brown NP, Draghi DC, Evangelista AT, Yee YC, Sahm DF. Antimicrobial activity among multidrug-resistant Streptococcus pneumoniae isolated in the United States, 2001-2005. Postgrad Med. 2008 Sep; 120(3 Suppl 1):32-8. PMID: 18931469.
      Citations:    
    153. Sahm DF, Brown NP, Thornsberry C, Jones ME. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective. Postgrad Med. 2008 Sep; 120(3 Suppl 1):16-24. PMID: 18931467.
      Citations:    
    154. Davies TA, Yee YC, Goldschmidt R, Sahm DF, Evangelista AT. Decline in the prevalence of pandemic clones Spain23F-1 and Spain9V-3 among US fluoroquinolone-resistant Streptococcus pneumoniae TRUST Surveillance isolates since 2001. Postgrad Med. 2008 Sep; 120(3 Suppl 1):39-45. PMID: 18931470.
      Citations:    
    155. Sahm DF, Brown NP, Yee YC, Evangelista AT. Stratified analysis of multidrug-resistant Escherichia coli in US health care institutions. Postgrad Med. 2008 Sep; 120(3 Suppl 1):53-9. PMID: 18931472.
      Citations:    
    156. Ge Y, Biek D, Talbot GH, Sahm DF. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother. 2008 Sep; 52(9):3398-407. PMID: 18625769.
      Citations:    
    157. Arhin FF, Tomfohrde K, Draghi DC, Aranza M, Parr TR, Sahm DF, Moeck G. Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters. Diagn Microbiol Infect Dis. 2008 Sep; 62(1):92-5. PMID: 18614315.
      Citations:    
    158. Pillar CM, Draghi DC, Dowzicky MJ, Sahm DF. In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest. J Clin Microbiol. 2008 Sep; 46(9):2862-7. PMID: 18596149.
      Citations:    
    159. Asbell PA, Sahm DF, Shaw M, Draghi DC, Brown NP. Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005. J Cataract Refract Surg. 2008 May; 34(5):814-8. PMID: 18471638.
      Citations:    
    160. Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother. 2008 Jul; 52(7):2383-8. PMID: 18443115.
      Citations:    
    161. Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J Antimicrob Chemother. 2008 Jul; 62(1):116-21. PMID: 18424792.
      Citations:    
    162. Tillotson GS, Draghi DC, Sahm DF, Tomfohrde KM, Del Fabro T, Critchley IA. Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study. J Antimicrob Chemother. 2008 Jul; 62(1):109-15. PMID: 18397923.
      Citations:    
    163. Asbell PA, Colby KA, Deng S, McDonnell P, Meisler DM, Raizman MB, Sheppard JD, Sahm DF. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol. 2008 Jun; 145(6):951-958. PMID: 18374299.
      Citations:    
    164. Draghi DC, Tench S, Dowzicky MJ, Sahm DF. Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance. Chemotherapy. 2008; 54(2):91-100. PMID: 18303257.
      Citations:    
    165. Arhin FF, Sarmiento I, Belley A, McKay GA, Draghi DC, Grover P, Sahm DF, Parr TR, Moeck G. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob Agents Chemother. 2008 May; 52(5):1597-603. PMID: 18299406.
      Citations:    
    166. Pillar CM, Aranza MK, Shah D, Sahm DF. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin. J Antimicrob Chemother. 2008 Mar; 61(3):595-602. PMID: 18218646.
      Citations:    
    167. Pillar CM, Draghi DC, Sheehan DJ, Sahm DF. Prevalence of multidrug-resistant, methicillin-resistant Staphylococcus aureus in the United States: findings of the stratified analysis of the 2004 to 2005 LEADER Surveillance Programs. Diagn Microbiol Infect Dis. 2008 Feb; 60(2):221-4. PMID: 17976944.
      Citations:    
    168. Murphy CK, Karginova E, Sahm D, Rothstein DM. In vitro activity of novel rifamycins against gram-positive clinical isolates. J Antibiot (Tokyo). 2007 Sep; 60(9):572-6. PMID: 17917240.
      Citations:    
    169. Sahm DF, Benninger MS, Evangelista AT, Yee YC, Thornsberry C, Brown NP. Antimicrobial resistance trends among sinus isolates of Streptococcus pneumoniae in the United States (2001-2005). Otolaryngol Head Neck Surg. 2007 Mar; 136(3):385-9. PMID: 17321864.
      Citations:    
    170. Goldstein BP, Draghi DC, Sheehan DJ, Hogan P, Sahm DF. Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother. 2007 Apr; 51(4):1150-4. PMID: 17220411.
      Citations:    
    171. Park CH, Robicsek A, Jacoby GA, Sahm D, Hooper DC. Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob Agents Chemother. 2006 Nov; 50(11):3953-5. PMID: 16954321.
      Citations:    
    172. Draghi DC, Sheehan DF, Hogan P, Sahm DF. Current antimicrobial resistance profiles among methicillin-resistant Staphylococcus aureus encountered in the outpatient setting. Diagn Microbiol Infect Dis. 2006 Jun; 55(2):129-33. PMID: 16542812.
      Citations:    
    173. Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob. 2006 Feb 09; 5:2. PMID: 16469106.
      Citations:    
    174. Davies TA, Yee YC, Goldschmidt R, Bush K, Sahm DF, Evangelista A. Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003). J Antimicrob Chemother. 2006 Mar; 57(3):437-42. PMID: 16431861.
      Citations:    
    175. Draghi DC, Sheehan DJ, Hogan P, Sahm DF. In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother. 2005 Dec; 49(12):5024-32. PMID: 16304168.
      Citations:    
    176. Davies TA, Bush K, Sahm D, Evangelista A. Predominance of 23S rRNA mutants among non-erm, non-mef macrolide-resistant clinical isolates of Streptococcus pneumoniae collected in the United States in 1999-2000. Antimicrob Agents Chemother. 2005 Jul; 49(7):3031-3. PMID: 15980393.
      Citations:    
    177. Slama TG, Amin A, Brunton SA, File TM, Milkovich G, Rodvold KA, Sahm DF, Varon J, Weiland D. A clinician's guide to the appropriate and accurate use of antibiotics: the Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteria. Am J Med. 2005 Jul; 118 Suppl 7A:1S-6S. PMID: 15993671.
      Citations:    
    178. Karlowsky JA, Jones ME, Thornsberry C, Evangelista AT, Yee YC, Sahm DF. Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies. Clin Infect Dis. 2005 Feb 15; 40 Suppl 2:S89-98. PMID: 15712102.
      Citations:    
    179. Johnson JR, Kuskowski MA, Gajewski A, Sahm DF, Karlowsky JA. Virulence characteristics and phylogenetic background of multidrug-resistant and antimicrobial-susceptible clinical isolates of Escherichia coli from across the United States, 2000-2001. J Infect Dis. 2004 Nov 15; 190(10):1739-44. PMID: 15499527.
      Citations:    
    180. Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit--a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob. 2004 Jul 29; 3:14. PMID: 15283864.
      Citations:    
    181. Flamm RK, Weaver MK, Thornsberry C, Jones ME, Karlowsky JA, Sahm DF. Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob Agents Chemother. 2004 Jul; 48(7):2431-6. PMID: 15215091.
      Citations:    
    182. Karlowsky JA, Jones ME, Draghi DC, Thornsberry C, Sahm DF, Volturo GA. Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002. Ann Clin Microbiol Antimicrob. 2004 May 10; 3:7. PMID: 15134581.
      Citations:    
    183. Wang M, Sahm DF, Jacoby GA, Zhang Y, Hooper DC. Activities of newer quinolones against Escherichia coli and Klebsiella pneumoniae containing the plasmid-mediated quinolone resistance determinant qnr. Antimicrob Agents Chemother. 2004 Apr; 48(4):1400-1. PMID: 15047552.
      Citations:    
    184. Ge Y, Wikler MA, Sahm DF, Blosser-Middleton RS, Karlowsky JA. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother. 2004 Apr; 48(4):1384-96. PMID: 15047550.
      Citations:    
    185. Wang M, Sahm DF, Jacoby GA, Hooper DC. Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob Agents Chemother. 2004 Apr; 48(4):1295-9. PMID: 15047532.
      Citations:    
    186. Jones ME, Draghi DC, Karlowsky JA, Sahm DF, Bradley JS. Prevalence of antimicrobial resistance in bacteria isolated from central nervous system specimens as reported by U.S. hospital laboratories from 2000 to 2002. Ann Clin Microbiol Antimicrob. 2004 Mar 25; 3:3. PMID: 15043754.
      Citations:    
    187. Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Nathwani D. Antibiotic susceptibility of bacteria most commonly isolated from bone related infections: the role of cephalosporins in antimicrobial therapy. Int J Antimicrob Agents. 2004 Mar; 23(3):240-6. PMID: 15164964.
      Citations:    
    188. Master RN, Draghi DC, Jones ME, Thornsberry C, Sahm DF, Karlowsky JA. Tracking the implementation of NCCLS M100-S12 expanded-spectrum cephalosporin MIC breakpoints for nonmeningeal isolates of Streptococcus pneumoniae by clinical laboratories in the United States during 2002 and 2003. Ann Clin Microbiol Antimicrob. 2004 Jan 08; 3:1. PMID: 14713319.
      Citations:    
    189. Sahm DF, Thornsberry C, Jones ME, Karlowsky JA. Factors influencing fluoroquinolone resistance. Emerg Infect Dis. 2003 Dec; 9(12):1651-4. PMID: 14725310.
      Citations:    
    190. Jones ME, Blosser-Middleton RS, Thornsberry C, Karlowsky JA, Sahm DF. The activity of levofloxacin and other antimicrobials against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999-2002. Diagn Microbiol Infect Dis. 2003 Dec; 47(4):579-86. PMID: 14711479.
      Citations:    
    191. Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Nathwani D. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents. 2003 Oct; 22(4):406-19. PMID: 14522104.
      Citations:    
    192. Wenzel RP, Sahm DF, Thornsberry C, Draghi DC, Jones ME, Karlowsky JA. In vitro susceptibilities of gram-negative bacteria isolated from hospitalized patients in four European countries, Canada, and the United States in 2000-2001 to expanded-spectrum cephalosporins and comparator antimicrobials: implications for therapy. Antimicrob Agents Chemother. 2003 Oct; 47(10):3089-98. PMID: 14506014.
      Citations:    
    193. Karlowsky JA, Jones ME, Draghi DC, Sahm DF. Clinical isolates of Streptococcus pneumoniae with different susceptibilities to ceftriaxone and cefotaxime. Antimicrob Agents Chemother. 2003 Oct; 47(10):3155-60. PMID: 14506024.
      Citations:    
    194. Karlowsky JA, Weaver MK, Thornsberry C, Dowzicky MJ, Jones ME, Sahm DF. Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol. 2003 Jul; 41(7):3339-43. PMID: 12843088.
      Citations:    
    195. Davies TA, Goldschmidt R, Pfleger S, Loeloff M, Bush K, Sahm DF, Evangelista A. Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000). J Antimicrob Chemother. 2003 Aug; 52(2):168-75. PMID: 12837740.
      Citations:    
    196. Karlowsky JA, Thornsberry C, Critchley IA, Jones ME, Evangelista AT, Noel GJ, Sahm DF. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob Agents Chemother. 2003 Jun; 47(6):1790-7. PMID: 12760850.
      Citations:    
    197. Critchley IA, Blosser-Middleton RS, Jones ME, Thornsberry C, Sahm DF, Karlowsky JA. Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001. Antimicrob Agents Chemother. 2003 May; 47(5):1689-93. PMID: 12709341.
      Citations:    
    198. Critchley IA, Sahm DF, Kelly LJ, Karlowsky JA. In vitro synergy studies using aztreonam and fluoroquinolone combinations against six species of Gram-negative bacilli. Chemotherapy. 2003 May; 49(1-2):44-8. PMID: 12714810.
      Citations:    
    199. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother. 2003 May; 47(5):1681-8. PMID: 12709340.
      Citations:    
    200. Karlowsky JA, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001. Antimicrob Agents Chemother. 2003 May; 47(5):1672-80. PMID: 12709339.
      Citations:    
    201. Karlowsky JA, Thornsberry C, Jones ME, Evangelista AT, Critchley IA, Sahm DF. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin Infect Dis. 2003 Apr 15; 36(8):963-70. PMID: 12684907.
      Citations:    
    202. Critchley IA, Draghi DC, Sahm DF, Thornsberry C, Jones ME, Karlowsky JA. Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J Antimicrob Chemother. 2003 Mar; 51(3):639-49. PMID: 12615866.
      Citations:    
    203. Jones ME, Karlowsky JA, Blosser-Middleton R, Critchley I, Karginova E, Thornsberry C, Sahm DF. Reinterpretation of susceptibility data using current NCCLS breakpoint criteria. Antimicrob Agents Chemother. 2003 Feb; 47(2):830. PMID: 12543705.
      Citations:    
    204. Karlowsky JA, Thornsberry C, Jones ME, Sahm DF. Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin. Clin Infect Dis. 2003 Jan 15; 36(2):183-7. PMID: 12522750.
      Citations:    
    205. Jones ME, Blosser-Middleton RS, Critchley IA, Karlowsky JA, Thornsberry C, Sahm DF. Activity of faropenem, a new furanem, against European respiratory pathogens collected during 2000-2001: a comparison with other beta-lactam agents. J Antimicrob Chemother. 2003 Jan; 51(1):196-9. PMID: 12493818.
      Citations:    
    206. Sahm DF, Thornsberry C, Karlowsky JA. The application of information technology to regional, national, and global surveillance of antimicrobial resistance. Curr Pharm Des. 2003; 9(12):969-74. PMID: 12678862.
      Citations:    
    207. Sahm DF. Resistance issues and community-acquired respiratory infections. Clin Cornerstone. 2003; Suppl 3:S4-11. PMID: 14992415.
      Citations:    
    208. Jones ME, Blosser-Middleton RS, Critchley IA, Thornsberry C, Sahm DF, Yamakita J, Akasaki M, Karlowsky JA. The activity of levofloxacin and comparator agents against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999 and 2000. Chemotherapy. 2002 Dec; 48(5):232-7. PMID: 12476039.
      Citations:    
    209. Karlowsky JA, Sahm DF. Antibiotic resistance - is resistance detected by surveillance relevant to predicting resistance in the clinical setting? Curr Opin Pharmacol. 2002 Oct; 2(5):487-92. PMID: 12324248.
      Citations:    
    210. Jones ME, Karlowsky JA, Blosser-Middleton R, Critchley I, Thornsberry C, Sahm DF. Relationship between antibiotic resistance in Streptococcus pneumoniae and that in Haemophilus influenzae: evidence for common selective pressure. Antimicrob Agents Chemother. 2002 Sep; 46(9):3106-7. PMID: 12183285.
      Citations:    
    211. Jones ME, Mayfield DC, Thornsberry C, Karlowsky JA, Sahm DF, Peterson D. Prevalence of oxacillin resistance in Staphylococcus aureus among inpatients and outpatients in the United States during 2000. Antimicrob Agents Chemother. 2002 Sep; 46(9):3104-5. PMID: 12183284.
      Citations:    
    212. Critchley IA, Blosser-Middleton RS, Jones ME, Karlowsky JA, Karginova EA, Thornsberry C, Sahm DF. Phenotypic and genotypic analysis of levofloxacin-resistant clinical isolates of Streptococcus pneumoniae collected in 13 countries during 1999-2000. Int J Antimicrob Agents. 2002 Aug; 20(2):100-7. PMID: 12297358.
      Citations:    
    213. Karlowsky JA, Draghi DC, Thornsberry C, Jones ME, Critchley IA, Sahm DF. Antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in two successive respiratory seasons in the US. Int J Antimicrob Agents. 2002 Aug; 20(2):76-85. PMID: 12297355.
      Citations:    
    214. Jones ME, Karlowsky JA, Blosser-Middleton R, Critchley IA, Karginova E, Thornsberry C, Sahm DF. Longitudinal assessment of antipneumococcal susceptibility in the United States. Antimicrob Agents Chemother. 2002 Aug; 46(8):2651-5. PMID: 12121949.
      Citations:    
    215. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother. 2002 Aug; 46(8):2540-5. PMID: 12121930.
      Citations:    
    216. Moellering RC, Craig W, Edmond M, Farrell DJ, Ferraro MJ, File TM, Klein J, Lonks J, Metlay JP, Sahm D, Talbot GH. Clinical and public health implications of macrolide-resistant Streptococcus pneumoniae. J Chemother. 2002 Jul; 14 Suppl 3:42-56. PMID: 12418560.
      Citations:    
    217. Jones ME, Critchley IA, Karlowsky JA, Blosser-Middleton RS, Schmitz FJ, Thornsberry C, Sahm DF. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV. Antimicrob Agents Chemother. 2002 Jun; 46(6):1651-7. PMID: 12019071.
      Citations:    
    218. Karlowsky JA, Kelly LJ, Critchley IA, Jones ME, Thornsberry C, Sahm DF. Determining Linezolid's baseline in vitro activity in Canada using gram-positive clinical isolates collected prior to its national release. Antimicrob Agents Chemother. 2002 Jun; 46(6):1989-92. PMID: 12019122.
      Citations:    
    219. Karlowsky JA, Critchley IA, Blosser-Middleton RS, Karginova EA, Jones ME, Thornsberry C, Sahm DF. Antimicrobial surveillance of Haemophilus influenzae in the United States during 2000-2001 leads to detection of clonal dissemination of a beta-lactamase-negative and ampicillin-resistant strain. J Clin Microbiol. 2002 Mar; 40(3):1063-6. PMID: 11880440.
      Citations:    
    220. Thornsberry C, Sahm DF, Kelly LJ, Critchley IA, Jones ME, Evangelista AT, Karlowsky JA. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis. 2002 Mar 01; 34 Suppl 1:S4-S16. PMID: 11810606.
      Citations:    
    221. Jones ME, Karlowsky JA, Blosser-Middleton R, Critchley IA, Thornsberry C, Sahm DF. Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiative. Int J Antimicrob Agents. 2002 Feb; 19(2):119-23. PMID: 11850164.
      Citations:    
    222. Sahm DF, Thornsberry C, Mayfield DC, Jones ME, Karlowsky JA. In vitro activities of broad-spectrum cephalosporins against nonmeningeal isolates of Streptococcus pneumoniae: MIC interpretation using NCCLS M100-S12 recommendations. J Clin Microbiol. 2002 Feb; 40(2):669-74. PMID: 11825993.
      Citations:    
    223. Critchley IA, Sahm DF, Thornsberry C, Blosser-Middleton RS, Jones ME, Karlowsky JA. Antimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999. Diagn Microbiol Infect Dis. 2002 Feb; 42(2):129-35. PMID: 11858909.
      Citations:    
    224. Critchley IA, Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Murfitt K, Sahm DF. Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother. 2002 Feb; 46(2):550-5. PMID: 11796376.
      Citations:    
    225. Karlowsky JA, Jones ME, Draghi DC, Critchley IA, Thornsberry C, Sahm DF. In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren. Diagn Microbiol Infect Dis. 2002 Jan; 42(1):59-64. PMID: 11821173.
      Citations:    
    226. Davies TA, Evangelista A, Pfleger S, Bush K, Sahm DF, Goldschmidt R. Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrob Agents Chemother. 2002 Jan; 46(1):119-24. PMID: 11751121.
      Citations:    
    227. Karlowsky JA, Critchley IA, Draghi DC, Jones ME, Thornsberry C, Sahm DF. Activity of cefditoren against beta-lactamase-positive and -negative Haemophilus influenzae and Moraxella catarrhalis. Diagn Microbiol Infect Dis. 2002 Jan; 42(1):53-8. PMID: 11821172.
      Citations:    
    228. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Evangelista AT, Critchley IA, Sahm DF. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network. Int J Antimicrob Agents. 2002 Jan; 19(1):21-31. PMID: 11814764.
      Citations:    
    Sahm's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (344)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _